Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox BID in Thalassemia Inadequate Responders
NCT01948817Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of deferasirox in thalassemia, sponsored by Novartis. Planned start Feb 2014; status: withdrawn.
02
Drugs
deferasirox
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT01948817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01948817.